Kasule, G. W., Kateete, D. P., & Joloba, M. L. (2016). Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families. BMC Infect Dis.
Chicago Style CitationKasule, George W., David P. Kateete, i Moses L. Joloba. "Mycobacterium Tuberculosis Uganda II Is More Susceptible to Rifampicin and Isoniazid Compared to Beijing and Delhi/CAS Families." BMC Infect Dis 2016.
Cita MLAKasule, George W., David P. Kateete, i Moses L. Joloba. "Mycobacterium Tuberculosis Uganda II Is More Susceptible to Rifampicin and Isoniazid Compared to Beijing and Delhi/CAS Families." BMC Infect Dis 2016.
Atenció: Aquestes cites poden no estar 100% correctes.